恒瑞医药：HRS-4729 注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances energy expenditure and lipid metabolism compared to dual-target products [1] - The drug aims to regulate glucose and lipid metabolism while suppressing appetite, leading to better weight loss and reduction of liver fat [1] - As of now, there are no similar products approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-4729 injection has reached approximately 39.62 million yuan [1]